Fed. Circ. Mulls Undoing Mylan Loss On Inhaler IP Validity
A Federal Circuit panel on Tuesday raised doubts about a district court decision upholding three patents covering AstraZeneca's inhaler asthma treatment Symbicort that Mylan stipulated to infringing with its planned generic...To view the full article, register now.
Already a subscriber? Click here to view full article